Sulprostone

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Summary

Sulprostone is a prostaglandin analogue used to treat post-partum hemorrhaging, induce medical abortion, and induce labour in instances of in utero fetal death.

Generic Name
Sulprostone
DrugBank Accession Number
DB12708
Background

Sulprostone has been used in trials studying Abortion, Induced.

Type
Small Molecule
Groups
Investigational
Structure
Weight
Average: 465.56
Monoisotopic: 465.182123516
Chemical Formula
C23H31NO7S
Synonyms
  • Sulprostone
External IDs
  • CP-34,089
  • CP-34089
  • ZK 57 671
  • ZK-57671

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Indication TypeIndicationCombined Product DetailsApproval LevelAge GroupPatient CharacteristicsDose Form
Induction ofFetal deaths in utero•••••••••••••••••••• •••••••••••• ••• ••••••••
Management ofPostpartum bleeding•••••••••••••• •••••••• •••••••• •••••••••••••• ••• ••••••••
Treatment ofPostpartum haemorrhage (pph)•••••••••••••••••••••• ••••••• ••• ••••••••
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
Carboprost tromethamineCarboprost tromethamine may increase the uterotonic activities of Sulprostone.
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now

Categories

ATC Codes
G02AD05 — Sulprostone
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as prostaglandins and related compounds. These are unsaturated carboxylic acids consisting of a 20 carbon skeleton that also contains a five member ring, and are based upon the fatty acid arachidonic acid.
Kingdom
Organic compounds
Super Class
Lipids and lipid-like molecules
Class
Fatty Acyls
Sub Class
Eicosanoids
Direct Parent
Prostaglandins and related compounds
Alternative Parents
Phenoxy compounds / Phenol ethers / Alkyl aryl ethers / Cyclopentanols / Organosulfonic acids and derivatives / Aminosulfonyl compounds / Cyclic ketones / Cyclic alcohols and derivatives / Carboxylic acids and derivatives / Organopnictogen compounds
show 3 more
Substituents
Alcohol / Alkyl aryl ether / Aminosulfonyl compound / Aromatic homomonocyclic compound / Benzenoid / Carbonyl group / Carboxylic acid derivative / Cyclic alcohol / Cyclic ketone / Cyclopentanol
show 18 more
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
501Q5EQ1GM
CAS number
60325-46-4
InChI Key
UQZVCDCIMBLVNR-TWYODKAFSA-N
InChI
InChI=1S/C23H31NO7S/c1-32(29,30)24-23(28)12-8-3-2-7-11-19-20(22(27)15-21(19)26)14-13-17(25)16-31-18-9-5-4-6-10-18/h2,4-7,9-10,13-14,17,19-20,22,25,27H,3,8,11-12,15-16H2,1H3,(H,24,28)/b7-2-,14-13+/t17-,19-,20-,22-/m1/s1
IUPAC Name
(5Z)-7-[(1R,2R,3R)-3-hydroxy-2-[(1E,3R)-3-hydroxy-4-phenoxybut-1-en-1-yl]-5-oxocyclopentyl]-N-methanesulfonylhept-5-enamide
SMILES
CS(=O)(=O)NC(=O)CCC\C=C/C[C@@H]1[C@@H](\C=C\[C@@H](O)COC2=CC=CC=C2)[C@H](O)CC1=O

References

General References
  1. AIFA Product Information: Nalador (sulprostone) powder for solution for infusion [Link]
PubChem Compound
5312153
PubChem Substance
347828906
ChemSpider
4471583
ChEBI
135755
ChEMBL
CHEMBL1472830
ZINC
ZINC000004474665
Wikipedia
Sulprostone

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
Not AvailableUnknown StatusNot AvailableMedically induced abortion1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
Injection, powder, for solutionIntravenous0.5 MG
Powder0.5 mg/1ampoule
Powder, for solutionParenteral0.5 MG
Powder, for solutionIntravenous500 mcg
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0296 mg/mLALOGPS
logP1.97ALOGPS
logP1.33Chemaxon
logS-4.2ALOGPS
pKa (Strongest Acidic)4.08Chemaxon
pKa (Strongest Basic)-2.9Chemaxon
Physiological Charge-1Chemaxon
Hydrogen Acceptor Count7Chemaxon
Hydrogen Donor Count3Chemaxon
Polar Surface Area130 Å2Chemaxon
Rotatable Bond Count11Chemaxon
Refractivity121.9 m3·mol-1Chemaxon
Polarizability48.36 Å3Chemaxon
Number of Rings2Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterYesChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-0f89-0006900000-3911b0cecd5512f1b76d
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-0002-1002900000-8e38a4fd6d7f9d1fdcac
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-003s-0029300000-48b8b52c3e02ffe6ddb4
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-0006-9002600000-f9344a3a68b3745f0a96
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-0006-9042200000-6a6597aa66988fc0d766
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-00ou-2119100000-db5e1baf3a0b6dc5f91f
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-205.27623
predicted
DeepCCS 1.0 (2019)
[M+H]+207.6718
predicted
DeepCCS 1.0 (2019)
[M+Na]+213.5843
predicted
DeepCCS 1.0 (2019)

Drug created at October 20, 2016 23:42 / Updated at June 08, 2021 11:32